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PU.1 Positively Regulates GATA-1 Expression in Mast Cells
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Amir Shahlaee,‡ Ye Ying,x Rodney DeKoter,{ and Michael A. McDevittx

M

ast cells are central effectors in the pathogenesis of
allergic and inflammatory disorders, and they also
participate in normal host defense (1–3). Mature mast
cells in the connective and mucosal tissues differentiate from
uncommitted hematopoietic stem cells in the bone marrow; this
process of lineage selection is orchestrated by a network of tightly
regulated transcription factors (4). Current models of hematopoiesis suggest that multiple lineage-specific transcription factors are
expressed at low levels in early, pluripotent progenitor cells.
During differentiation, subsets of these transcription factors become dominantly expressed in a lineage-restricted fashion. It is
increasingly recognized that antagonistic programs provide decision trees through binary switches and more complex antagonistic pathways. Activation of one program leads to antagonism
and repression of the other. One example is the relationship between the GATA-1 and PU.1 transcription factors. GATA-1 is an
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essential transcriptional regulator for the erythroid and megakaryocyte lineages (5–8), whereas it is absent in neutrophils and
monocytes. GATA-1 requires interaction with the cofactor FOG-1
for erythroid and megakaryocyte development. However, FOG-1
has been shown to antagonize mast cell development (9, 10), and
it inhibits the expression of GATA-1–dependent mast cell-specific
genes (11). Alternatively, PU.1 is a critical transcription factor for
neutrophils and monocytes (12, 13), but it is downregulated during
erythroid differentiation. Reciprocal activation of GATA-1 and
PU.1 in early, multipotent progenitors restricts differentiation
potential to either the megakaryocyte/erythroid or lymphoid/myeloid lineages, respectively (14, 15). Furthermore, these two factors have been shown to be antagonistic in monocytic and
erythroid cells; however, both GATA-1 and PU.1 are required for
the normal development of the mast lineage (16, 17).
The mechanisms by which these factors are coexpressed and might
cooperate in mast cell differentiation are poorly understood. A
number of studies have demonstrated the functional antagonism
between PU.1 and the GATA factors. Forced expression of GATA-1
into myelomonocytic cells reprograms their differentiation to erythroid cells, eosinophils, or megakaryocytic precursors (18, 19).
Conversely, PU.1 overexpression represses erythroid differentiation
(20, 21). The mechanism of antagonism appears to be due to direct
interactions between the DNA binding domains of these proteins.
GATA-1 has been shown to inhibit transcriptional activity of PU.1
through direct physical interactions that result in displacement of the
PU.1 coactivator c-Jun (22, 23). PU.1 appears to interfere with the
expression of GATA-1–dependent targets by disrupting of the ability
of GATA-1 to bind DNA (23). Although these two factors are antagonistic, they are coexpressed at low levels in multipotential hematopoietic precursors in what can be considered a priming stage
(24). During lineage selection to either myeloid or erythroid, PU.1
or GATA-1 is upregulated selectively to become the dominantly
expressed factor in the respective lineages. Mast cells are unique in
that both PU.1 and GATA-1 are coexpressed and required for proper
maturation. This suggests that unique mast cell-specific mechanisms
are in play to regulate these factors.
GATA-1 expression is controlled by highly conserved regulatory
elements. Two well-characterized mRNA isoforms of GATA-1
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Coexpression of PU.1 and GATA-1 is required for proper specification of the mast cell lineage; however, in the myeloid and erythroid
lineages, PU.1 and GATA-1 are functionally antagonistic. In this study, we report a transcriptional network in which PU.1 positively
regulates GATA-1 expression in mast cell development. We isolated a variant mRNA isoform of GATA-1 in murine mast cells that is
significantly upregulated during mast cell differentiation. This isoform contains an alternatively spliced first exon (IB) that is distinct
from the first exon (IE) incorporated in the major erythroid mRNA transcript. In contrast to erythroid and megakaryocyte cells, in mast
cells we show that PU.1 and GATA-2 predominantly occupy potential cis-regulatory elements in the IB exon region in vivo. Using
reporter assays, we identify an enhancer flanking the IB exon that is activated by PU.1. Furthermore, we observe that in PU.12/2 fetal
liver cells, low levels of the IE GATA-1 isoform is expressed, but the variant IB isoform is absent. Reintroduction of PU.1 restores
variant IB isoform and upregulates total GATA-1 protein expression, which is concurrent with mast cell differentiation. Our results are
consistent with a transcriptional hierarchy in which PU.1, possibly in concert with GATA-2, activates GATA-1 expression in mast cells
in a pathway distinct from that seen in the erythroid and megakaryocytic lineages. The Journal of Immunology, 2010, 184: 4349–4361.
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Materials and Methods
Cells
Murine embryonic stem cells were differentiated into mast cells according
to the method described previously (34). Strain 129v murine embryonic
stem cells were grown on a feeder layer of mitomycin-treated mouse

embryonic fibroblasts in DMEM (GIBCO, Grand Island, NY) supplemented with 15% ES grade FBS (HyClone, South Logan, UT), 1% penicillin/streptomycin and glutamine, 100 mM b mercaptoethanol, 1 mM
sodium pyruvate, 1% nonessential amino acids (GIBCO) and 100 U/ml of
mouse recombinant LIF (Chemicon International, Temecula, CA). Embryonic stem cells were adapted to IMDM (GIBCO) with supplements as
listed above and grown on 0.2% gelatin coated plates prior to differentiation. To differentiate embryonic stem cells, 5000 cells were plated on
bacterial-grade Petri dishes in 1.5 ml IMDM with 0.9% methylcellulose
(StemCell Technologies, Vancouver, Canada) supplemented with 15% ES
grade FBS, 1% penicillin/streptomycin and glutamine, 434 mM monothioglycerol, 1 mM sodium pyruvate, 1% nonessential amino acids, with
50 ng/ml SCF and 5 ng/ml of IL-11. After 1 wk, developing embryoid
bodies were supplemented with culture media containing 60 ng/ml SCF,
30 ng/ml mouse recombinant IL-3, and 30 ng/ml IL-6. At week 2 of
culture, embryoid bodies were transferred to tissue culture flasks and allowed to differentiate in DMEM supplemented with 10% FCS, 1% penicillin/streptomycin and glutamine, 20% WEHI supernatant, 50 ng/ml SCF.
Mast cells were identified by their morphologic appearance on light microscopy. The percentage of differentiated mast cells was obtained by
counting over 500 cells from 3 independent experiments. Bone marrowderived mast cells (BMMCs) were derived from 4–8-wk-old wild type
C57/BL6 mice. Mice were maintained in The Johns Hopkins University
Animal Facilities in accordance with institutional guidelines. Bone marrow
obtained from femurs and tibias and splenocytes obtained from spleens
from these mice were cultured in DMEM with 10% FCS supplemented
with 1% penicillin/streptomycin and glutamine as well as 20% WEHI
supernatant and 50 ng/ml of mouse recombinant SCF as previously described (35). The HMC-1 human mast cell lines and the L8057 murine
megakaryocytic cell lines were maintained in RPMI 1640 with 10% FBS
and 1% penicillin/streptomycin and glutamine. The HeLa cell lines, the
murine erythroleukemia MEL cell lines, and the NIH 3T3 murine fibroblast cell lines were maintained in DMEM with 10% FBS and 1% penicillin/streptomycin and glutamine. The C57 murine mast cell line was
maintained in DMEM with 10% FBS and 1% penicillin/streptomycin and
glutamine and 5 3 1025 M b mercaptoethanol. The PU.12/2 fetal liver
cells were described previously (16). These cells are maintained in RPMI
1640 (GIBCO) supplemented with 10% FBS (Sigma-Aldrich, St. Louis,
MO), 1% penicillin/streptomycin and glutamine (GIBCO), and 100 mM b
mercaptoethanol with 5 ng/ml of recombinant murine IL-3.

Plasmids
The pMMP-IRES-puro retroviral vector has been described previously (34).
pMMP-IRES-puro PU.1 was constructed by subcloning the PU.1 cDNA
into the pMMP-IRES-puro backbone. The pEBB expression constructs
have been described previously (35). pEBB GATA-1, pEBB GATA-2, and
pEBB PU.1 were constructed by subcloning the cDNAs for GATA-1,
GATA-2, and PU.1 into the pEBB backbone. The inserts were amplified by
PCR with an Nde site engineered at the 59 end and a Cla1 site engineered
at the 39 end. The reporter assays were constructed by cloning genomic
fragments of the GATA-1 locus into the xho1 kpn1 site of the pGL2 pro
vector. Mutations in the PU.1 binding site were created with the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) according to manufacturer’s recommendations. The core GGAA sequences
were mutated to TCGC. The primers used to amplify by PCR the genomic
fragments are as follows: pUE luciferase forward 59-GTC AAA CAC ATG
ACT CCT TGG T-39, reverse 59-GGT GCT GGA CTC ATA TCC CAT-39:
pIEP luciferase forward 59-CCC CAG CCC CAA GAC AGC CT-39, reverse 59-GTC TCC CTT CTC TCC CTC CTG CCA-39: pGP2 luciferase
forward 59-CCA AAC CCC AAA CAG ATC TC-39, reverse 59-GGC CTG
GAC TTC TCA CCT TT-39: pIBb luciferase forward 59-GCA GTG TGG
GGG CAG GAG-39, reverse 59-GGC AGA ATG CAG GAC CAA G-39:
pIBa luciferase forward 59-AGT GGT GAG ACT CAA AGG-39, reverse
59-GGC AGA ATG CAG GAC CAA G-39: pIBds luciferase forward 59CTT GGT CCT GCA TTC TGC CT-39, reverse 59-TGT GTG TCT CCT
TTT GGG C-39: phu IBds luciferase forward 59-TCT GGT CCT GCA
TGC CAT CCC-39, reverse 59-TCC TTT TTC TCC TCC ACC TTC-39.

Retroviral transduction of PU.1 fetal liver cells
Retrovirus was produced using the method described by Ory et al. (36). The
293GPG cell line was grown in 15-cm tissue culture plates with DMEM
supplemented with 10% FBS, 1% penicillin/streptomycin and glutamine,
and 1 mg/ml doxycycline. The 293GPG cell line was transfected with 25 mg
pMMP-IRES-puro-PU.1 and 75 mg FuGENE 6 (Life Technologies). Medium was replaced daily and doxycycline was removed to induce expression
of VSV-G. Supernatant was collected on days 4–8 after transfection. Retrovirus was concentrated by centrifuging supernatant at 26,000 3 g in
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arise from alternatively spliced noncoding first exons that are under
the control of tissue-selective promoters: the promoter proximal to
the IE exon is active in hematopoietic cells (25), and the IT
promoter is primarily used in the testis (26). The IE GATA-1
isoform appears to be the major isoform in hematopoietic cells;
the expression of this isoform in erythroid cells and megakaryocytes is dependent on hypersensitive regions upstream of the
transcriptional start site (27, 28). Eosinophils also express and
require GATA-1 for normal development. A targeted deletion of
a region upstream of the IE exon, which contains a highly conserved GATA binding site palindrome, results in a selective deficiency of eosinophils (29), while mast cells, erythroid cells, and
megakaryocytes are spared. In contrast, deletion of first enhancer
(hypersensitive site I) and distal promoter of the GATA-1 gene
leads to abnormal erythroid, megakaryocyte, and mast cell development, but eosinophil differentiation is not affected (30). The
existence of cell-specific enhancers and/or mRNA isoforms allows
for cell-specific expression of these transcription factors; however,
the regulatory elements that control GATA-1 expression in mast
cells have not been explored.
In addition to GATA-1, a number of transcription factors have been
demonstrated to play essential roles in mast cell development. PU.1
is an ETS family transcription factor that is a critical regulator of the
myeloid and lymphocyte lineages. Mouse embryos with a targeted
deletion of PU.1 lack skin mast cells (16). Furthermore, fetal liver
cells deficient in PU.1 cannot differentiate into the earliest mast cell
precursors. Restoration of mast cell differentiation is dependent on
the expression of PU.1 and GATA-2 (16). GATA-2 is a zinc finger
transcription factor similar to GATA-1. Murine embryonic stem
cells deficient in GATA-2 do not differentiate into mast cells, illustrating its requirement for early commitment to the mast lineage
(31). In contrast to GATA-2 and PU.1, GATA-1 appears important
for terminal differentiation. The hypomorphic GATA-1 low mutation (deletion of upstream enhancer and distal promoter) results in
increased proliferation and impaired differentiation of mast cell
progenitors (17, 32). The different developmental phenotypes of
these mutations suggest that these transcription factors act at different stages of mast cell differentiation.
The goal of this study was to investigate the regulation of GATA1 in mast cells. We identified a unique mRNA isoform of GATA-1
that is abundantly expressed during mast cell development. Based
on the requirement of PU.1 and GATA-2 for early mast cell development, we speculated that these factors might participate in the
regulation of GATA-1 in mast cells. Using a computational approach (33), we identified consensus GATA and PU.1 binding sites
within phylogenetically conserved regions of the GATA-1 gene.
We determined whether the GATA and PU.1 factors bound these
putative sites in vivo and ex vivo with chromatin immunoprecipitation (ChIP) and EMSA, respectively. Potential regulatory regions were examined with reporter assays. We examined the
physiologic requirement of PU.1 for the IB GATA-1 isoform expression in mast cells using PU.1-deficient fetal liver cells and
show an absolute requirement for PU.1. This work demonstrates
that PU.1 regulates GATA-1 expression in mast cells; both PU.1
and GATA-2 occupy mast cell specific cis-regulatory elements in
the GATA1 gene. The findings support a model for a transcriptional network regulating GATA-1 in mast cells that is distinct
from that in erythroid cells and megakaryocytes.

GATA-1 REGULATION IN MAST CELLS

The Journal of Immunology
an ultracentrifuge for 1.5 h. Concentrated retrovirus was resuspended in
TEN buffer overnight at 4˚C. PU.1 fetal liver cells were transduced with
concentrated retrovirus (100–200 ml) with 8 mg/ml polybrene for ∼24 h.
Retroviral transduction was repeated twice, after which cells were resuspended in fresh media with IL-3 at 5 ng/ml and SCF at 50 ng/ml. After 2–3
d in culture, 2 mg/ml puromycin was added and maintained in culture to
select for stably transduced cells.

Real-time quantitative PCR

59 RACE
mRNA was isolated from the C57 mast cell line and the M1 myeloid cell line
using the mRNA isolation kit (Stratagene). 59RACE was performed using
the SMART RACE cDNA amplification kit (BD Biosciences, San Jose,
CA) according to manufacturer’s recommendations. The 39 primer used
for amplification of 59 RACE products was CGC TCC GTC TTC AAG
GTG TCC AAG AAC G.

RNase protection assay
Total RNA was extracted from the C57 mast cell line with Trizol (Invitrogen). RNase protection assays were performed using the RiboQuant RPA
kit (BD Biosciences) according to manufacturer’s recommendations. The
RNA antisense probe used to determine the transcriptional initiation site
was made with the RiboQuant In Vitro Transcription Kit (BD Biosciences,
Mississauga, Ontario, Canada). The template for in vitro transcription was
constructed by PCR amplification of the genomic sequence of the GATA-1
intron and subcloning into the pCR2.1 (Invitrogen) vector. The 59 primer
for PCR was upstream of the IB exon (GAT AAA GCC GGA AAC CAC
GGG) and the 39 primer was within the IB exon (CGG CAA GCC TTT

GCT TCT CTT TCT), which amplified a 243-bp product. The resultant
RNA probe was 311 bp because of an additional 68 bp of vector sequence.

EMSAs
Nuclear extracts were extracted from the mast cell line C57 and from COS
cells transfected with the expression constructs pEBB GATA-1, pEBB
GATA-2, pEBB PU.1, and pEBB vector. COS cells were transfected using
the DEAE-dextran method as previously described (35); 5 mg DNA was
mixed with a 2.5 mM chloroquine and 0.1% DEAE-dextran solution and
added to 5 ml DMEM with 10% FBS. The mixture was added to a 10-cm
plate of COS cells for 4 h at 37˚C, and the media was replaced with 10%
DMSO in PBS for 2 min at room temperature. The solution was removed
and fresh media were added. Cells were harvested after 72 h, and nuclear
extracts were obtained as described (38). Double-stranded oligonucleotide
probes were synthesized and are as follows with the GATA and PU.1
binding sequences underlined: UE G 59-GCC CCC GCT GAT TCC CTT
ATC TAT GCC TTC CCA GC-39; UE- 59-ACA GGG ATG GGG GAG
GGA ATG GGG TGA GGC CTG TC-39; IE GG 59-GAG TCC ATC TGA
TAA GAC TTA TCT GCT GCC CCA G-39; GI GG 59-CCA GCC TGG
AGA TAA ACT TTA TCT CTG TCC GGA-39; IB- 59-GGG TGA TTT
CAA AAG TTG GGC GGG GAT GGC AGA GA-39; IB G1 59-GCG GGG
ATG GCA GAG ATA AGC AGT GTG GGG GCA-39; IB G2 59-CAA GAT
ACA ACA GAT AGG GAT GAA GTT GGG GAG CA-39; Ms IB P1 59TTA CTC TTC TCA GAG GAA GCC AGT AGC TTT GG-39; Ms IB P2
59-CCA TAG AAC AGG GAG GAA CTA ACG GGG CCC ACA-39; Ms
IB P3 59-GAA GAG AGA ATA AAA AGA GGA AAT GGA GGA GGC
CTT-39; Ms IB P4 59-AGG CTT GCC GGA GGA GGA GAA AGA GGA
AGG TTA GAA GGA-39; Ms IB P5 59-GAG GAG ACA CAG AAA GAG
GAA GAG AAA TAT GGT AC-39; Ms IB P6 59-CAA GAC AGT GGA
AAG AGG AAA AGG GGA AGA AAA-39; Hu IB P3 5-AGA ATA AGA
GGA AGT GGA GGA GG-39; Hu IB P5 59-GTA GAC AGG GGA AGA
GAG GCC-39. For PU.1-mutated probes, the GGAA core sequence was
changed to TCGC. Oligonucleotide probes were end-labeled with T4
polynucleotide kinase (New England Biolabs, Beverly, MA) with g[32P]
ATP according to manufacture’s instructions. Gel shift analysis was performed as previously described (35). Reactions were performed in 20 ml
volumes with 5% glycerol, 100 mM KCl, 10 mM Tris-Cl (pH 7.4), 1 mM
dithiothretol, 0.3 mg of poly(dI-dC), and ∼5 3 105 cpm of [32P]-end labeled oligonucleotide probe. Supershift analysis was done with 4 mg Ab
against GATA-1 (N6 clone), GATA-2 (H-116 clone), and PU.1 (T-21
clone). All Abs were from Santa Cruz Biotechology, Santa Cruz CA and at
a concentration of 200 mg/0.1 ml. For no-Ab controls, 4 mg BSA was used.
The reactions were separated on 4.5% PAGE with 0.53 TBE with 0.1%
glycerol as buffer.

Reporter assays
Transfections of the HMC-1 human mast cell line were performed with the
Superfect reagent (Qiagen, Valencia, CA) according to the manufacturer’s
recommendation. Briefly, 3 3 105 cells were placed in 1500 ml RMPI 1640
with 10% FBS in 24-well plates; 4 ml Superfect solution was added to 2 mg
DNA to make a total volume of 100 ml in OptiMEM. The drive-to-reporter
ratio was 1:4. Sea pansy luciferase 0.05 mg was added to the Superfect:
DNA mixture for normalization and the mixture was allowed to incubate at
room temperature for 15 min; 1200 ml RPMI with 10% FBS was added to
the mixture and then added to the cells. Cells were incubated overnight at
37˚C and lysates were harvested the following day in 150 ml of passive
lysis buffer (Promega, Madison, WI). Transfections of the HeLa cell line
were performed with the Effectene Transfection reagent (Qiagen) according to manufacturer’s recommendation. Briefly, 1 3 105 cells were
plated in 500 ml DMEM with 10% FBS in 24-well plates. A total of 0.5 mg
DNA was used at DNA-to-reagent ratio of 1:25. The driver-to-reporter
ratio was 1:4. Sea pansy luciferase (0.1 mg) was used for normalization.
Cells were incubated overnight with the DNA:Effectene complexes at
37˚C, and lysates were harvested the following day in 150 ml passive lysis
buffer (Promega). For both HMC-1 and HeLa transfections, 20 ml lysate
was assayed for luciferase activity using the dual luciferase system
(Promega). All experiments were done in triplicate and normalized to sea
pansy luciferase activity.

Results
An alternative GATA-1 isoform is expressed in murine mast
cells and myeloid cells
As the first step in characterizing the potential regulation of GATA1 in mast cells, we performed 59RACE in a well-characterized
murine mast cell line C57. Two abundant RACE products were
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RNA was harvested from cells with Trizol (Invitrogen), and cDNA was
made with the first-strand synthesis kit (Invitrogen); 1–5 mg RNA was used
as starting material for synthesis. Real-time quantitative PCR was performed using a SYBR green mix (BioRad, Hercules, CA) on an iQ5
multicolor real-time PCR detection system (Bio-Rad, Hercules, CA).
Primers were optimized for temperature and were used at a concentration
of 200 nM. The primers sequences are as follows: IE GATA-1 forward 59CCC TGA ACT CGT CAT ACC ACT AAG-39, IB GATA-1 forward 59AAA CTC CTA TGG GAG CTG TCA AGG-39: GATA-1 common forward
59-ATC AGC ACT GGC CTA CTA CAG AG-39, GATA-1 reverse 59-GAG
AGA AGA AAG GAC TGG GAA AG-39: PU.1 forward 59-AGA GCA
TAC CAA CGT CCA ATG C-39: PU.1 reverse 59-GTG CGG AGA AAT
CCC AGT AGT G-39: GATA-2 forward 59-CAA GAA AGG GGC TGA
ATG TTT CG-39: GATA-2 reverse 59-GTG TCC CAC AGG TGC CAT G39: b actin forward 59-GTG ACG AGG CCC AGA GCA AGA G-39: b
actin reverse 59-AGG GGC CGG ACT CAT CGT ACT C-39. Conventional
PCR primers and conditions for IE GATA-1, IB GATA-1, GATA-1 common, GATA-2, PU.1, and b actin are the same used for real-time quantitative PCR. Relative quantification of mRNA of GATA-1, GATA-2, and
PU.1 between the mast cell line, erythroid line, megakaryocyte line, and
fibroblast line was determined by taking the ratio of the signal divided by
the signal of b actin from that cell line, and then scaling to a mast cell
signal of 1. For the GATA-1 IE and IB relative signals, the ratio of the b
actin normalized GATA-1 IE or IB signals to the b actin normalized
GATA-1 common signal was determined.
Scanning chromatin immunoprecipitation was performed as previously
described (37). The name of the ChIP primers denotes the position in kb
relative to the GATA-1E start site. Primer sequences are listed as follows:
242 forward 59-ACA GAA CTA TCC ATT GGA CCA AAC T-39, 242
reverse 59-ACC ACA TCC ACA CAG TCA GTA AAA G-39: 232.5 forward 59-GCG TGC CCC ATG TCT CA-39, 232.5 reverse 59-GGC TAA
AAA GCT TGG CAC ACA-39: 225 forward 59-TGC ATG CAT TTC
CCT AAC TAC TGT-39, 225 reverse 39-CCT CCA TCG CTT TAC TGT
CAC TT-39: 24 (HS UE) forward 59-CCT GCT GGC TGA ACT GTG-39,
4 (HS UE) reverse 39-TGG TGT GGT GCT GGA CTC-39: 0 (HS IE)
forward 59-AAA GAA GTG TAT GTA CCC TTA CCC-39, 0 (HS IE)
reverse 59-CGT GAG CCC TCC TGA ATG C-39: +2 59-TCC TTC CCT
TAA ACT CCA CAG C-39, +2 reverse 59-TGG TAG TTA GGA GGT TAG
AGG TAG-39: +3.5 (HS IB) forward 59-AGT CAG ATG GCA AGA TAC
AAC AG-39, reverse +3.5 (HS IB) 39-TCC TCC TTT ACT TTC CTT CTA
ACC-39: +8 forward 59-GGT TAC ACC CCT GTC TTC CTC C-39, +8
reverse 59-GCT CAC AAG AGA TCC ACC TGC-39: +19 forward 59-CCC
ATT CAG GAG ACA CTG TCC-39, reverse +19 59-GTC AGA AAG CCC
GAC TTT CG-39: +38 59-ACA GTG CGT GAC ATC TCA AGC-39, +38
reverse 59-GTG GCC CAA TGT TCT GAC C-39. Cycling parameters were
for quantitative PCR was as follows: 95˚C for 30 s, 50˚–65˚C for 30 s, 72˚
C for 30 s. Forty cycles were performed.
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amplified and sequenced: a ∼600-bp product and a larger ∼700-bp
product (Fig. 1A). Analysis of the sequences demonstrated that the
smaller product was the isoform of GATA-1 containing the IA
exon found predominantly in erythroid cells; the larger product,
however, was an isoform of GATA-1 that contained a distinct
exon. Sequence analysis of ∼30 independently derived 59 RACE
products demonstrated that this isoform incorporated a noncoding
first exon that was alternatively spliced onto exon II. Previous
work has described a similar exon IB (25), initially identified in
a rare transcript expressed in erythroleukemia cells. Additional
studies showed an exon IB-containing transcript in primary murine myeloid colony cells (39) and eosinophils (40). These larger

transcripts that we identified by RACE are compared with previously identified transcripts in Fig. 1D. The IB exon lies 3.7 kb
downstream of the IE exon and is in close proximity to a previously identified hypersensitive site (41). Sequence analysis of
multiple C57 59RACE products demonstrates that the complete IB
exon in mast cells is considerably longer than what was previously
described. On inspection of the sequences upstream of IB, no
TATA boxes were identified. The 39 end of IB was invariant with
a splice donor site 736 bp upstream of the major GATA-1 AUG
codon. We also identified the IB isoform in the myeloid cell line,
M1, a murine leukemia cell line (42) by 59RACE (data not
shown). 59RACE products of variable lengths were identified,
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FIGURE 1. A variant mRNA isoform of GATA-1 is expressed in murine mast cells. A, Abundant 59RACE products of GATA-1 from the murine mast cell
line C57. Products were separated on a 1.2% agarose gel and stained with ethidium bromide. Sequence analysis revealed that the ∼600-bp product was the
exon IE containing isoform of GATA-1, and the ∼700-bp product was the exon IB containing isoform. B, Schematic representation of the IE and IB isoforms.
These isoforms arise for a differential splicing event that places the untranslated first exon onto exon II. The translational start ATG lies within exon II for both
isoforms. The RNase probe contains 243 bp of sequence from the IB exon (black bar) and an additional 68 bp of vector sequence (yellow bar). The resultant
probe length was 311 bp. The major protected probe is 155 bp in length. The 39RACE primer lies within exon III. C, RNase protection assay demonstrating
multiple protected bands in the C57 murine mast cell line. The total probe length is 311 bp in length (243 bp of exon IB sequence plus 68 bp of vector
sequence). The major protected probe size is 155 bp long (arrow). D, Sequence of GATA-1 isoform identified by 59RACE from murine mast cells. The
transcriptional start site was determined by RNase protection (based on the major probe fragment of 155 bp) and denoted with a +1. The initial nucleotide of
the most common transcript represented in sequenced RACE products is denoted with a v (above nucleotide) and extends 135 bp upstream of exon 2. The
initial nucleotide of the longest transcript represented in sequenced RACE products is denoted by ^ (below nucleotide) and extends 212 bp upstream of exon 2.
A shorter transcript described previously by Seshasaye et al. (39) is shown with an * (above nucleotide) and extends 78 bp upstream of exon 2. The exon IB and
exon II are underlined and capitalized. An open reading frame begins in exon II and the translated amino acids are depicted. Consensus GATA sites are
highlighted in yellow and PU.1 sites (GGAA) are highlighted in blue. Consensus binding sites that are contained within oligonucleotide EMSA probes are
boxed and labeled. EMSA probes containing consensus sites that are conserved between mouse and human are denoted by an *. IBP1, IBP2, IBP3, IBP4, IBP5,
IBP6 refer to EMSA probes with a PU.1 binding motif. IBG1 and IBG2 refer to EMSA probes with a GATA binding motif.
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suggesting possible heterogeneity in the transcriptional start
site, as has been described for the IE exon (25). To delineate the
59 end of the IB exon, we used RNase protection. As shown in
Fig. 1C, we found multiple products that were protected in mast
cells, with a predominant fragment (155 bp in length) that
mapped a transcriptional start site to 179 bp upstream of exon 2
(Figs. 1B–D). We conclude that the multiple bands represent
the presence of variable transcript lengths and possible probe
degradation.
We examined the tissue-specific expression of this isoform
during mast cell development with RT-PCR using isoform specific
primers. Murine embryonic stem cells were differentiated in vitro
in culture conditions suitable for mast cell differentiation (43), and
RNA was harvested at various time points during the culture

process. As shown in Fig. 2A, the IE exon-containing isoform of
GATA-1 can be detected throughout development. However, the
IB exon-containing isoform of GATA-1 can be detected only after
week 3 of culture, when .80% of the cells are morphologically
identifiable mast cells (Fig. 2A). We also assessed by quantitative
PCR the relative expression of the GATA-1 isoforms in other cell
types that express GATA-1. As shown in Fig. 2B, the IE exoncontaining GATA-1 isoform is expressed in erythroid cells (MEL
cell line), megakaryocytes (L8057 cell line), and mast cells (C57
cell line and primary BMMCs). However, the fraction of the IB
exon-containing isoform comprises a significantly greater percentage of the total GATA-1 signal in mast cells (34% for C57 and
37% for primary mast cells) compared with erythroid (10%) and
megakaryocyte (13%) lines (Fig. 2B).

FIGURE 3. Putative transcription factor binding sites for GATA and PU.1 in the murine GATA-1 locus. Three genomic regions conserved between the
mouse and human are depicted in the murine GATA-1 locus: the upstream enhancer, the exon IE promoter, the GATA palindrome within the first intron, and the
hypersensitive site in proximity to exon IB. These sites correspond to previously identified DNaseI hypersensitive sites (labeled HS UE, HS IE, HS IB; see text
for details). Putative GATA sites are denoted by rectangles, and PU.1 sites are denoted by black ovals. The GATA palindromic sites are depicted by stars. The
regions spanned by PCR primers for ChIP are shown with gray bars. Sites of the EMSA probes used in Fig. 4 are depicted at the bottom of the figure and the
denoted by black bars. The UE and IB control probes do not have consensus PU.1 or GATA binding sequences. dnhuP3 and huP5 denote EMSA probes from
human sequence that are homologous to the murine corresponding murine probes (msP3 and msP5, respectively). Exons are shown by stippled bars.
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FIGURE 2. The IB GATA-1 isoform is upregulated during mast cell differentiation. A, Murine embryonic stem cells were differentiated in vitro, and the
expression of GATA-1 isoforms was determined by RT-PCR. The IE GATA-1 isoform can be detected in undifferentiated cells and is sustained during
differentiation. The IB GATA-1 isoform can be detected only when morphologically identifiable mast cells appear. Cytospin preparations of differentiated
embryonic stem cells were stained with Wright-Giemsa. Quantification of mast cell differentiation was done by visual identification of cells expressing
metachromatic granules stained with Wright-Giemsa. Photomicrograph images were acquired with a Kontron ProgRes 3012 digital camera and Roche Image
analysis software with a Zeiss Axiophot microscope. Original magnification 340. B, Relative expression of GATA-1 isoforms in cells expressing GATA-1.
Quantitative PCR with SYBR green was performed in a murine mast cell line (C57), primary BMMCs, a murine megakaryocyte line (L8057), and a murine
erythroleukemia line (MEL). Fraction of IE and IB isoform was calculated by taking the IE or IB signal and dividing by the sum of the IE and IB signals.
Signals were normalized to b actin. IB GATA signal is detected from all cell types, but mast cells express significantly more IB GATA relative to total GATA-1.
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FIGURE 4. EMSAs demonstrate GATA-2 and PU.1 binding to consensus binding sites. Regions of EMSA probes are denoted in Figs. 1D and 3. COS
cells were transfected with GATA-1, GATA-2, PU.1, or vector alone. EMSAs were performed with nuclear extracts from transfected COS cells and C57
mast cells with [32P]-labeled oligonucleotide probes containing consensus DNA binding sites for transcription factors. Specific binding was determined by
supershifting Abs. Specific GATA-2 complex is denoted by ^, and GATA-1 complex by ^^. PU.1 complexes are depicted by + and ++. A background band is
denoted by *. The free probe is marked by **. A, GATA factor binding to the upstream enhancer region in vitro. GATA-1 and GATA-2 bind the UE G probe
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however, the degree of conservation between murine, rat and human is diminished. Within the IB exon and intron, two GGAA sites
were conserved between mouse and human (IBP3* and IBP5*).
Based on published role of GATA factors and PU.1 in mast cell
development, we focused further studies on these conserved GATA
and PU.1 sites as possible regulatory elements in mast cells.
GATA-2 binds the GATA-1 locus in vitro
Since prediction algorithms are only a first step in identifying
functional elements, we used EMSA to examine the capacity for
GATA factors and PU.1 to bind to the highly conserved putative
DNA binding sites in the GATA-1 locus. To assess the DNA
binding of each hematopoietic factor individually—without the
potential influence of GATA factor/PU.1 complex formation—
GATA-1, GATA-2, and PU.1 were individually expressed in COS
cells, which do not express any of these factors. Specificity of
binding was determined by supershifting Abs. Probes containing
single conserved GATA sites from the upstream enhancer region
(UE G) and 59 flanking region of the IB exon (IB G1 and IB G2),
as well as probes containing the palindromic GATA sites from the
IE promoter (IE GG) and GATA-1 intron (GI GG), were bound by
both GATA-1 (Fig. 4A–C, supershifted band denoted by ^^) and
GATA-2 (Fig. 4A–C, supershifted band denoted by ^) expressed in
COS. We found that the GATA-2 supershifting Ab showed crossreactivity with GATA-1, as noted by the less intense COS-transfected
GATA-1/GATA probe complex recognized by the GATA-2 Ab
(Fig. 4A–C, probes UE G, IE GG, G1 GG, and IB G2). We also
found that the PU.1 Ab recognized a complex of COS-transfected
GATA-1 nuclear extracts with several GATA site-containing
probes (Fig. 4A, 4B, probes UE G and G1 GG). The identity of the
proteins within this complex is not clear. In our hands, the PU.1
Ab does not recognize GATA-1 protein by either immunoprecipitation or western blot, and no PU.1 protein can be detected by
Western blot in the COS-transfected GATA-1 nuclear extracts
(Supplemental Data, Supplemental Fig. 2). Possible explanations
include the presence of a cross-reacting protein in COS cells that
is recognized by the PU.1 Ab; this protein may bind to transfected
GATA-1 bound to probe, or the protein may be induced when
GATA-1 is expressed.
We then examined DNA binding capacity of GATA factors from
mastcellnuclearextracts.Incontrast tothenuclear extractsfromCOS
cells, only GATA-2 from mast cells extracts, and not GATA-1, bound
putative GATA sites efficiently (Fig. 4A–C). We confirmed protein
expression of GATA-1 in mast cell extracts as well as transfected
COS cell extracts (Fig. 5C, Supplemental Data, Supplemental
Fig. 2). These findings raise the possibility for tissue-specific posttranslational modifications of GATA factors that might affect DNA
binding activity and/or the assembly of multiprotein complexes in
mast cells necessary for optimal binding to these sequences.

containing a conserved GATA binding site. The UE is a negative control without GATA or PU.1 sites. Whereas GATA-1 and GATA-2 from COS cells bound
consensus GATA sites, only GATA-2 from mast cell extracts bound this site. B, GATA factor binding to the IE promoter region in vitro. GATA-1 and GATA-2
bind both the IE GG and G1GG probes, which contain the highly conserved GATA palindromic binding sites. Only GATA-2 from mast cell extracts bind
these GATA sites. C, GATA binding to the exon IB upstream region in vitro. GATA-1 and GATA-2 bind the IB G1 and IB G2 probes which contain
conserved GATA binding site. No binding is detected by PU.1 to the IB P1 and IB P2 probes, which contain conserved PU.1 sites. Probe IB is a negative
control probe without GATA or PU.1 sites. Only GATA-2 from mast cell extracts bind these GATA sites. D, PU.1 binding to the exon IB downstream
region. PU.1 binds probes containing GGAA core motifs from the murine sequence (ms IBP3, ms IBP4, ms IBP5, and ms IBP6). E, PU.1 also binds to
probes with the GGAA core motifs from the human sequence with 59flanking sequence that is conserved with murine sequence (hu IBP3). Probe hu IB P5
contains the core GGAA sequence, but does not contain the conserved 59 flanking sequence. Regions of the probes from the IB region are depicted in Fig.
1D. Cross-reactivity of the GATA-2 Ab with COS-transfected GATA-1 protein is noted in probes UE G, IE GG, G1 GG and IB G2. A background band is
also noted with the PU.1 Ab and COS-transfected GATA-1 extracts with the UE G and G 1 GG probe. BSA, (negative control); G1, GATA-1; G2, GATA-2.
E, Flanking sequence to core PU.1 motif specify PU.1 binding. The core GGAA motif of the IB probes are aligned and shaded light gray. Probes that bind
PU.1 share a 59 flanking aaga sequence motif and are shaded dark gray. hu IB P5 binds PU.1, but does not share this 59 flanking motif.
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To examine the potential transcriptional regulation of the IB containing GATA-1 isoform in mast cells, we first used TRANSFAC
(www.gene-regulation.com/index.html) to inspect ∼110,000 bp of
human and murine GATA-1 sequences that compose the locus and
found several hundred GATA and PU.1 sites, including those previously identified (27, 28, 41, 44). To focus the pool of possible
sites to investigate, we used an independent analysis with the
TRAFAC program (33), which has been used to identify conserved
and functional Myc (37) and other transcription factor binding sites.
Again, a number of consensus GATA and PU.1 sites were identified, although much fewer (Supplemental Data, Supplemental Fig.
1). This analysis in particular identified stretches of conserved
sequences in close proximity to three previously identified hematopoietic-specific regulatory sites. These sites corresponded to
previously determined DNase I-hypersensitive sites (Fig. 3, Supplemental Fig. 1). A high degree of conservation was identified
∼3.5–4 kb upstream of the IE promoter. This region contains an
upstream enhancer that has been demonstrated to be a DNase Ihypersensitive site in hematopoietic cells. It has been referred to
previously as hypersensitive site I (44) and more recently HS-3.5
(41). For this study, we will refer to it as hypersensitive site upstream enhancer (HS UE). It contains a GATA binding site that is
conserved between mouse and human and shown by mutation to be
critical for expression of GATA-1 in transgenic hematopoietic
tissues (44). Within the erythroid promoter, ∼700 bp upstream of
the IE exon, a stretch of highly conserved sequence coincides with
another hypersensitive site, previously called hypersensitive site III
(44) or IE (41). We refer to this as the hypersensitivity site upstream
of the IE exon (HS IE) because of its proximity to the IE exon and
promoter (Fig. 3). This region contains a highly conserved GATA
palindromic binding sequence and other sequences necessary for
expression of GATA-1 in eosinophils (29). In addition, we found
another phylogenetically conserved region downstream of the IE
exon that also contained a GATA palindrome binding site (Fig. 3,
Supplemental Fig. 1). The IB exon mapped to a highly conserved
region within the GATA-1 intron; this had been previously demonstrated to be a DNase I hypersensitive site, named HS+3.5 (41).
We refer to the site as HS IB. Computational analysis identified
several putative GATA and PU.1 binding sites within this area; the
highest degree of phylogenetic conservation is found at the 59 region of the IB exon. Two consensus GATA binding sites were
identified upstream of the IB exon; these were both conserved in
humans (Fig. 1D, labeled IBG1* and IBG2*, highlighted yellow).
Two conserved putative PU.1 sites (labeled IBP1* and IBP2*,
highlighted blue) were also found in this region. The 39 flanking
sequences of the IB exon contains a GA-rich region (45) with
numerous potential PU.1 binding sites (Fig. 1D, highlighted blue);
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FIGURE 5. GATA-2 and PU.1 bind highly conserved sites of the GATA-1 gene in mast cells in vivo. A, ChIP were performed in murine cell lines:
fibroblast line (NIH 3T3), megakaryocyte line (L8057), erythroleukemia line (MEL), and mast cell line (C57). Relative binding is measured by the
quantitative genomic PCR signal normalized to the no-Ab signal for each PCR primer pair. The x-axis is labeled with the relative distances in kilobases
from the transcriptional start site of the IE exon. The positions of exons IE, IB, and exons II through VI of the GATA-1 gene are denoted by vertical lines at
the bottom of the figure. ChIP for acetylated histones H3 and H4 show areas of open chromatin around the GATA1 gene in megakaryocyte, erythroid, and
mast cell lines. There is relatively little acetylated histone binding in fibroblasts. B, In vivo binding of GATA-1, GATA-2, and PU.1 to conserved regions of
the GATA-1 gene. GATA-2 binds highly conserved regions in mast cells. PU.1 and GATA-2 co-occupy a highly conserved region in proximity to the IB
exon in murine mast cells. C, Protein expression of murine GATA-1, GATA-2, and PU.1 in murine cell lines determined by Western blot analysis. a-Tubulin
blot shows equivalent loading. GATA-1, GATA-2, and PU.1 protein is coexpressed in mast cell line C57. D, Protein expression of murine GATA-1, GATA2, and PU.1 in primary murine mast cells show coexpression in BMMCs and peritoneal mast cells.
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PU.1 and GATA-2 bind the GATA-1 locus in vivo in mast cells
To determine the capacity, specificity, and localization of potential
PU.1 and GATA factor binding to GATA-1 locus regulatory
sequences in mast cells, we performed scanning chromatin immunoprecipitation (37). Immunoprecipitation with Abs to the
acetylated histones H3 and H4 to determine open areas of chromatin (46, 47) was first performed. As expected and shown in Fig.
5A, acetylated histones bound the genomic regions corresponding
to previously identified hypersensitive sites in the GATA-1 locus
in primary erythroid cells, the MEL erythroleukemia cell line, and
the L8057 megakaryocyte cell line (41). The same regions were
open in the murine C57 mast cell line. There is minimal acetylated
histone binding detected in the NIH 3T3 fibroblast cell line, in
which GATA-1 is not expressed, except in a region in close
proximity to the ubiquitously expressed HDAC6 promoter, which
had been previously shown (41). Next, Abs for PU.1, GATA-1,
and GATA-2 were used to determine in vivo binding of these
tissue-specific transcriptional regulatory factors to highly conserved regions in the GATA-1 locus. As shown in Fig. 5B, GATA2 occupies regions surrounding the IE and IB exons in mast cells.
PU.1 appears to occupy only the region of the IB exon, but not the
IE exon. GATA-1, however, did not bind appreciably to these
regions. In MEL cells, GATA-1 was bound within the vicinity of
the upstream hypersensitivity (HS UE) region, consistent with the
findings reported by Valverde-Garduno et al. (41); in contrast, we
did not find appreciable GATA-1 binding to the IE and IB regions
in MEL cells. The MEL cells are erythroleukemia cells with high
expression of PU.1 (Fig. 5C). We also found that PU.1 occupied

the GATA-1 IB region in MEL cells. Unlike mast cells, however,
the IB region in MEL cells was not co-occupied by GATA-2. We
examined the expression of PU.1, GATA-1, and GATA-2 in these
cell types. As shown in Fig. 5C, the C57 mast cell line expressed
all these factors abundantly at the protein level. Primary murine
mast cells, (bone marrow derived mast cells and peritoneal mast
cells, see Fig. 5D) and human mast cells (HMC-1 and skin mast
cells) (48) also express these transcription factors. In addition,
GATA-1, GATA-2, and PU.1 were readily detected from the
murine megakaryocyte line (L8057). The murine erythroleukemia
cell line MEL is transformed by activation of PU.1 expression,
and thus high levels of PU.1 are detected in addition to GATA-1.
A significant amount of GATA-2 protein is not seen in MEL cells,
and the fibroblast line does not express these transcription factors
(Fig. 5C).
PU.1 activates a genomic region flanking the IB GATA-1 exon
To determine the potential functional activity of the genomic
regions binding GATA-2 and PU.1 in vivo, we performed reporter
assays in the human mast cell line, HMC-1 and the human epithelial cell line, HeLa. Genomic sequences containing the highly
conserved regions of the murine GATA-1 genome were placed
upstream and downstream of the SV40 promoter-containing reporter, pGL2pro. These genomic fragments included the upstream
enhancer (UE) region, the promoter of the IE exon (IEP), the GP2,
and the area 59 of the IB exon (IBa and IBb) and the downstream
area 39 of the exon (IBds; Fig. 6A). Although GATA-2 was found
to bind the upstream enhancer, the 59 region of the IB exon, and
the GATA palindrome sites both in vivo and ex vivo, neither
GATA-2 nor GATA-1 could activate transcription of genomic
fragments containing these sites in luciferase assays in HMC-1
(Fig. 6B). These murine genomic regions also contained putative
PU.1 binding sites (not conserved); similarly, PU.1 did not activate luciferase reporters with these genomic fragments in HMC-1.
In contrast, both GATA-1 and GATA-2, as well as PU.1, were able
to activate transcription of these genomic fragments in HeLa (Fig.
6C). Expression of transfected proteins were confirmed by Western blotting (Supplemental Data, Supplemental Fig. 4)
We found that PU.1 was able to activate transcription from a GArich genomic sequence downstream of the IB exon that was homologous between mouse and human (reporter construct IBds; Fig.
6B, 6C, Supplemental Data, Supplemental Fig. 5). The human
genomic region contains two PU.1 binding sites and the murine
region contains four PU.1 binding sites that were verified by
EMSA. This region was also bound in vivo by PU.1 in murine
mast cells. The capacity for PU.1 to transactivate the murine sequence did not depend on the orientation of the sequence, which is
consistent with enhancer function. Mutations of single PU.1 sites
did not significantly reduce transactivation potential of PU.1.
However, mutations of all four PU.1 binding sites abrogated the
ability of PU.1 to activate this sequence (Fig. 6D). PU.1 activation
of the human sequence was also independent of orientation in
HeLa. In HMC-1, PU.1 transactivated this human genomic region
when placed upstream of the luciferase gene; however, it did not
significantly transactivate when placed downstream (Supplemental
Data, Supplemental Fig. 5). Cotransfection of the GATA factors
with PU.1 into HMC-1 or HeLa cells did not result in synergistic
transcriptional activation (data not shown). These findings suggest
that regulation by the GATA factors and PU.1 may be cell typedependent. These data show that conserved cis-elements downstream of the IB exon are regulated by PU.1, but the in vivo
control of GATA-1 expression in mast cells likely depends on
other genomic elements and appropriate chromatin structure that
may not be accounted for in these assays.
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In the IB region, we examined PU.1 binding to conserved (boxed
sequences denoted by * in Fig. 1D) and nonconserved sites. Highly
conserved consensus PU.1 sites between mouse and human were
identified in the 59 flanking region of exon IB; however, probes
containing these sequences (IB P1 and IB P2) were not bound by
COS-expressing PU.1 (Fig. 4C). The 39 region of the IB exon was
extremely GA-rich with multiple consensus PU.1 sites (GGAA
sequences). The IBP3 probe from both mouse and human sequences contained conserved GGAA sites and formed a specific
complex (Fig. 4D, 4E, denoted by ++) that was supershifted the
PU.1 Ab (denoted by +). The IBP5 probe also contained a GGAA
core sequence that was conserved in mouse and human, but only the
mouse sequence bound PU.1 with high affinity (Fig. 4D, 4E).
Notably, the 59 sequences that flanked the GGAA core was not
conserved between human and mouse in this region. Other putative
PU.1 sites within the murine sequence that were not conserved in
humans (IBP4 and IBP6) were also able to bind COS-transfected
PU.1 protein (Fig. 4D). However, with nuclear extracts from murine mast cells, we were able to demonstrate binding with only one
probe (IBP5). We confirmed that PU.1 binding to probe sequences
was dependent on the GGAA core; bound complexes were competed with wild-type probe, but not with a probe with the GGAA
core mutated to TCGC (Supplemental Data, Supplemental Fig. 3).
The observation that PU.1 did not bind to all of the predicted
consensus PU.1 sites ex vivo suggested specificity imposed by
flanking sequences or cooperative recruitment scenarios. We visually inspected the sequences that flanked the core GGAA binding
motif. Probes that bound strongly to PU.1 shared an aaga sequence
59 to the core motif (Fig. 4F, shaded in dark gray). No shared
consensus was identified in sequences 39 to the core GGAA
binding motif. These results suggest that the aagaGGAA sequence
within the GATA-1 locus represented a high-affinity binding site
for PU.1. We next tested in vivo binding of GATA factors and
PU.1 to the GATA-1 locus cis-elements.
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PU.1 is required for the expression of the mast cell isoform of
GATA-1
Fetal liver cells derived from PU.12/2 mice can be maintained in
culture with IL-3, but they cannot differentiate into mast cells.
Restoration of PU.1 expression rescues the capacity for mast cell
development (16). We examined the expression of the GATA-1
isoforms in PU.12/2 fetal liver cells by RT-PCR. As shown in Fig.
7D, the IE exon containing isoform of GATA-1, but not the IB
exon containing isoform, is expressed in PU.1 deficient cells.
GATA-2 is also expressed in these cells as previously described
(16) (Fig. 7B, Supplemental Data, Supplemental Fig. 6). By
Western blot, GATA-1 protein is detectable in the PU.12/2 cells,
but at a much lower level than in mast cells. Retrovirally expressed PU.1 in the PU.12/2 cells cultured in IL-3 and SCF for 2
wk differentiate into mast cells, by expression of granules morphologically, and by expression of IgE receptor and c-Kit by flow
cytometry. Concurrent with differentiation, we found that restoration of PU.1 resulted in expression of the IB isoform of GATA-1
(Fig. 7D). Furthermore, total GATA-1 protein also appeared to be

upregulated with PU.1 expression (Fig. 7C). This finding suggested that PU.1 directly or indirectly targeted the IB isoform of
GATA-1 in mast cells, but was not required for IE expression. We
have also retrovirally restored expression of GATA-1 into the
PU.12/2 fetal liver cells; however, GATA-1 expression alone in
the absence of PU.1 does not rescue mast cell differentiation by
morphologic or flow cytometric analysis (data not shown). This
finding suggests that PU.1 targets other factors in addition to
GATA-1 to regulate mast cell differentiation.

Discussion
In this study, we have investigated the regulation of GATA-1 expression in mast cells. We have identified the full length sequence
of the variant murine IB GATA-1 isoform, and we found that this
isoform is abundantly expressed in mast cells. Our studies suggest
that PU.1, and possibly GATA-2, may be the critical regulators of
GATA-1 expression in mast cells, based on the demonstration of
in vivo and in vitro binding to conserved genomic elements of the
GATA-1 gene. Furthermore, reporter assays and in vivo studies
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FIGURE 6. PU.1 transactivates a conserved region downstream of the mast cell exon. A, Schematic representation of the GATA-1 gene with genomic
regions used for reporter assays. Conserved transcription factor binding sites are shown. GATA binding sites are denoted by rectangles; PU.1 binding sites are
denoted by black ovals; GATA palindrome sites are denoted by stars. UE, upstream enhancer; IEP, IE promoter; GP2, GATA palindrome within GATA-1
intron; IBds, genomic region downstream of the IB exon. B, Reporter assays in the human mast cell line, HMC-1 showing transactivation potential of GATA-1,
GATA-2, and PU.1 on the various genomic regions. Genomic fragments were placed in the pGL2pro vector, which has a SV40 promoter upstream of the
luciferase gene. Neither GATA-1 nor GATA-2 transactivate conserved regions with GATA sites in HMC-1. PU.1 transactivates a conserved region downstream
of the IB exon. The sequence is activated by PU.1 when placed downstream (IBds) or upstream (IBds rev) of the luciferase gene. C, Reporter assays in the
human epithelial cell line HeLa. In contrast to HMC-1 cells, both GATA-1 and GATA-2 transactivate conserved GATA sites in HeLa. Similar to HMC-1, PU.1
also transactivates the conserved region downstream of the IB exon in HeLa cells in both orientations (IBds and IBds rev). This downstream IB region does not
contain GATA sites and is not activated by the GATA factors. The other regions (UE, IEP, GP2, IBa, and IBb) contain GGAA sequences and are activated by
PU.1 in HeLa, but not HMC-1. D, Reporter constructs with single mutations in each of the four PU.1 binding sites in the region downstream of the IB exon are
activated by PU.1 in HeLa cells. However, mutations of all four PU.1 binding sites abrogates the ability of PU.1 to transactivate this reporter. Black ovals
denote PU.1 binding sites, and white rectangles denote GATA binding sites. The x denotes mutated PU.1 binding site.
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with PU.1-deficient cells support the hypothesis that murine IB
exon expression is dependent on PU.1. These findings suggest
a model in which PU.1 and possibly GATA-2, two transcription
factors critical for early mast cell differentiation, cooperate to
regulate the expression of a downstream transcriptional regulator,
GATA-1, through mast cell regulatory elements. This a mechanism
might explain the conundrum of how the antagonistic PU.1 and
GATA factors are coexpressed in mast cells. Our studies define
a regulatory network linking the GATA factors and PU.1 in mast
cells.
Our findings suggest that binding of the GATA factors to the
GATA-1 locus is dependent on cell type. Both GATA-1 and GATA2 bind consensus GATA motifs in vitro. However, in mast cells,
only GATA-2 can be demonstrated to occupy these regions both
in vitro (with nuclear extracts from mast cells) and in vivo (by
ChIP). This observation suggests that mast cell-specific complexes
may constrain DNA recognition. The GATA factors activate
transcription of luciferase reporters containing conserved GATA
sites in a non-mast cell line (HeLa); these sites lie within regions
important for GATA-1 expression in erythroid cells. However,
GATA factors do not activate reporters containing these conserved
sites when transfected in a mast cell line (HMC-1). Although we
show in vivo and in vitro binding of GATA-2 to the GATA-1 locus,
our data demonstrate the capacity of only PU.1, and not GATA-2, to
transactivate the GATA1 gene. These findings might suggest the
presence of mast cell factors that negatively regulate GATA
transcriptional activity on the erythroid promoters/enhancers or
the requirement of additional enhancers. Another possibility is
that the endogenous GATA-2 expression in HMC-1 might blunt
enhancement of transactivation by transfected GATA proteins.
However, we have found that the basal transcriptional activity of
reporters with GATA-site containing cis-elements do not differ
significantly from empty vector reporters (data not shown). This
finding suggests that endogenous GATA-2 expression in HMC-1

cells does not have significant transcriptional activity on the
GATA-site containing reporters. Furthermore, because reporter
assays might not reflect the influence of chromatin configuration
or regulation by long-distance enhancers, additional studies are
needed to clarify the role of GATA-2 in the regulation of GATA-1.
Transcription factor binding might also be influenced by conserved sequences that flank core binding motifs. We have demonstrated high-affinity binding of PU.1 in vitro to the core GGAA
sequence flanked at its 59 end by AAGA. These sequences are
found within conserved regions of the GATA-1 locus that are
occupied in vivo by PU.1 in mast cells. This particular sequence
motif has also been validated to be a binding site within promoters
and enhancers of a number of confirmed PU.1 target genes in both
myeloid and lymphoid cells (49). Additional studies are needed to
determine whether this motif regulates PU.1-dependent activation
of other critical mast cell genes.
An important negative finding was that forced expression of
GATA-1 did not rescue mast cell differentiation in PU.12/2 fetal
liver cells. This result suggests that GATA-1 requires the expression of other PU.1 target genes to specify the mast cell lineage.
Consistent with this notion is the finding that PU.1 deficient cells
are immature and do not express any typical markers of mast cell
differentiation (16). In contrast, GATA-1 null cells have the capacity to develop into mature mast cells in culture, whereas
GATA-1–deficient mast cells hyperproliferate, but do not terminally differentiate in vivo. We speculate that PU.1 regulates other
genes that are critical for the early stages of mast cell development
in addition to GATA-1. Another potential reason that GATA-1
does not restore mast cell differentiation in the absence of PU.1 is
a possible cooperative interplay between PU.1 and GATA-1. In
myeloid and erythroid cells, PU.1 and GATA-1 are antagonistic;
PU.1 is dominantly expressed during myeloid development and
GATA-1 is upregulated in erythroid differentiation. However, both
GATA-1 and PU.1 are required for specification of normal mast
cells. Based on this model, forced expression of GATA-1 in the
absence of PU.1 would be insufficient to rescue mast cell development. The mechanisms of this potential cooperativity between GATA-1 and PU.1 require further investigation.
We have previously shown that, in fetal liver and yolk sac, the
chromatin in both the IE and IB regions is open (4). Other investigators have also identified open chromatin that is sensitive to
DNase I close to the IB start site in a multipotential hematopoietic
progenitor cell line FDCP-mix (45). In this study, we show that the
IE isoform is expressed at low levels in undifferentiated, murine
embryonic stem cells, whereas the IB isoform is selectively upregulated during mast cell differentiation. These findings support
the notion of a “primed” state of pluripotent cells, in which low
levels of GATA-1 and other lineage-specific transcription factors
are expressed. During commitment to the erythroid or mast cell
lineage, the IE isoform or the IB isoform, respectively, is upregulated. Our studies show that PU.1 is not needed for IE expression, but it is required for IB expression. This finding fits a model
in which the myeloid transcription factor PU.1 upregulates the
expression of GATA-1 in murine mast cells and eosinophils
through the IB exon.
The differential expression of the noncoding IE and IB exons in
hematopoietic cell types indicate the presence of cell-specific cisregulatory elements. Given that the IE and IB isoforms are predicted to code for identical proteins, the physiologic importance of
this genomic organization may be to permit tissue-specific GATA1 expression. Although we have not identified a human ortholog of
the IB isoform from human mast cell lines, the 59 flanking sequences of the IB exon is highly conserved between species. We
have demonstrated that conserved PU.1 motifs from both mouse
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FIGURE 7. PU.1 is required for GATA-IB expression. A, PU.12/2 fetal
liver cells cannot differentiate into mast cells. Retroviral restoration of PU.1
expression rescues mast cell differentiation. Cytospin preparation of cells
stained with toluidine blue. Photomicrograph images were acquired with
a Kontron ProgRes 3012 digital camera and Roche Image analysis software
(Roche, Tuscon, AZ) with a Zeiss Axiophot microscope (Carl Zeiss,
Thornwood, NY). Original magnification 340. Western blot shows restoration of protein levels of PU.1. B, Western blot shows GATA-2 expression
in PU.12/2 cells that does not change significantly with reconstitution with
PU.1. C, Western blot shows upregulation of GATA-1 at the protein level
with PU.1 expression. a-Tubulin shows equivalent loading. D, PU.1 upregulates IB GATA-1 expression. RT-PCR analysis of GATA-1 isoforms
shows expression of IE GATA-1 isoform in undifferentiated cells, but no
expression of IB GATA-1. The expression of IB GATA-1 is upregulated with
restoration of PU.1 expression. b-actin shows equivalent loading.
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and human sequences in the IB region bind PU.1 in vitro. Furthermore, reporter constructs containing the murine and human
conserved cis-element can also be transactivated by PU.1 (Supplemental Data, Supplemental Fig. 5). This region has also been
found to be DNase 1 hypersensitive and bound by acetylated
histones in both mouse and human hematopoietic cells (41). This
evidence supports a conserved role for these sequences in the
regulation of GATA-1 expression. Thus, the shared biologic
function of this enhancer in humans and mice might be the upregulation of GATA-1 expression in mast cells during differentiation; in human mast cells, this upregulation might occur through
a GATA-1 transcript other than the IB isoform.
The upstream enhancer of GATA-1 is critical for proper expression of GATA-1 in erythroid cells and megakaryocytes (7, 27,
28, 44). A targeted deletion of this site in mice (the GATA-1 low
mouse mutant) also results in an abnormal mast cell phenotype
(17, 32). Intriguingly, proper eosinophil development does not
appear to be dependent on this enhancer (30). We have examined
the expression of GATA-1 in primary bone marrow-derived cells
from the GATA-1 low mouse. Both IE and IB isoforms are detectable in these mast cells, suggesting that the expression of either of these isoforms is not solely dependent on this enhancer
(data not shown). The role that the upstream enhancer plays in the
regulation of GATA-1 expression during mast cell development is
currently under investigation. In this study, we found that GATA2, and not GATA-1, bind conserved genomic regions of the upstream enhancer in mast cells both in vitro and in vivo. Surprisingly, neither GATA-2 nor GATA-1 activated upstream enhancer
sequences containing conserved GATA sites in reporter assays in
mast cells, suggesting that proper chromatin configuration is developmentally regulated and/or other transcription factor complexes participate in the expression of the gene in vivo.
One of the critical questions that remain is how GATA-2 might
cooperate with PU.1 to regulate critical mast cell targets in vivo.
In vivo GATA-2 and PU.1 binding sites are not in close proximity
within the GATA-1 locus. The majority of sites occupied by GATA2 are in conserved regions upstream of the IB exon. The two closest
sites bound by GATA-2 and PU.1 are separated by ∼250 bp. We
cannot, however, rule out the possibility of long-range interactions
between these two factors in vivo. Another possible mechanism to
explain their shared requirement for development is that either or
both of these factors might be altering chromatin configurations
that regulate access of other transcription factors to the GATA1
gene. Further analysis of the consensus binding sites and flanking
regions recognized by GATA-2 and PU.1 will provide insight into
sequence recognition specificity in mast cells and other factors
that might co-occupy the gene that participates in its regulation.
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45. Ronchi, A., M. Cirò, L. Cairns, L. Basilico, P. Corbella, P. Ricciardi-Castagnoli,
M. Cross, J. Ghysdael, and S. Ottolenghi. 1997. Molecular heterogeneity of
regulatory elements of the mouse GATA-1 gene. Genes Funct. 1: 245–258.
46. Litt, M. D., M. Simpson, M. Gaszner, C. D. Allis, and G. Felsenfeld. 2001.
Correlation between histone lysine methylation and developmental changes at
the chicken beta-globin locus. Science 293: 2453–2455.
47. Anguita, E., J. Hughes, C. Heyworth, G. A. Blobel, W. G. Wood, and
D. R. Higgs. 2004. Globin gene activation during haemopoiesis is driven by
protein complexes nucleated by GATA-1 and GATA-2. EMBO J. 23: 2841–2852.
48. Babina, M., Y. Schülke, L. Kirchhof, S. Guhl, R. Franke, S. Böhm, T. Zuberbier,
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